Potential of Low Dose Leuco-Methylthioninium Bis(Hydromethanesulphonate) (LMTM) Monotherapy for Treatment of Mild Alzheimer's Disease: Cohort Analysis as Modified Primary Outcome in a Phase III Clinical Trial

Journal of Alzheimer's Disease

Volumn 61, Issue 1, 2018, Pages 435-457

  Wilcock, Gordon K ^a   Gauthier, Serge ^b   Frisoni, Giovanni B ^c   Jia, Jianping ^d   Hardlund, Jiri H ^e   Moebius, Hans J ^f   Bentham, Peter ^g   Kook, Karin A ^h   Schelter, Bjoern O ⁱ   Wischik, Damon J ^j   Davis, Charles S ^k   Staff, Roger T ^l   Vuksanovic, Vesna ^l   Ahearn, Trevor ^l   Bracoud, Luc ^m   Shamsi, Kohkan ⁿ   Marek, Ken ^o   Seibyl, John ^o   Riedel, Gernot ^l   Storey, John M D ^e,i   Harrington, Charles R ^e,l   Wischik, Claude M ^e,l   more..

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF GENEVA   (Switzerland)

^d BEIJING INSTITUTE FOR BRAIN DISORDERS   (China)

^e TAURX THERAPEUTICS LTD   (United Kingdom)

^f Moebius Consult   (Switzerland)

^g BIRMINGHAM AND SOLIHULL MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^h Salamandra LLC   (United States)

ⁱ UNIVERSITY OF ABERDEEN   (United Kingdom)

^j UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^k CSD Biostatistics   (United States)

^l UNIVERSITY OF ABERDEEN   (United Kingdom)

^m BioClinica Inc   (United States)

ⁿ RadMD   (United States)

^o MNI   (United States)

more..

Author keywords

ADAS cog; Alzheimer's disease; amyloid protein; clinical trial; cohort study; methylthioninium; tau protein; treatment

Indexed keywords

FOLIC ACID; LEUCO METHYLTHIONINIUM BIS(HYDROMETHANESULPHONATE); MEMANTINE; NOOTROPIC AGENT; UNCLASSIFIED DRUG; LEUCOMETHYLENE BLUE; METHYLENE BLUE; NEUROLEPTIC AGENT;

ADD ON THERAPY; AGED; ALZHEIMER DISEASE; ANEMIA; ANXIETY DISORDER; ARTICLE; BACKACHE; BASAL FOREBRAIN; BRAIN ATROPHY; BRAIN SIZE; CLINICAL DEMENTIA RATING; CLINICAL OUTCOME; COHORT ANALYSIS; COMPARATIVE STUDY; CONFUSION; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSURIA; EYE DISEASE; FATIGUE; FEMALE; FOLIC ACID BLOOD LEVEL; FOLIC ACID DEFICIENCY; FRONTAL LOBE; HEADACHE; HEART DISEASE; HUMAN; INNER EAR DISEASE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; PARIETAL LOBE; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; POLLAKISURIA; PONS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SIDE EFFECT; SKIN DISEASE; TEMPORAL LOBE; TREATMENT DURATION; URINARY TRACT INFECTION; URINE INCONTINENCE; VASCULAR DISEASE; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DEMENTIA ASSESSMENT; DIAGNOSTIC IMAGING; DOUBLE BLIND PROCEDURE; INTERNATIONAL COOPERATION; MIDDLE AGED; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; COHORT STUDIES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTERNATIONAL COOPERATION; MALE; MENTAL STATUS AND DEMENTIA TESTS; METHYLENE BLUE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 85036556784     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-170560     Document Type: Article

References (56)

1. Murray ME, Lowe VJ, Graff-Radford NR, Liesinger AM, Cannon A, Przybelski SA, Rawal B, Parisi JE, Petersen RC, Kantarci K, Ross OA, Duara R, Knopman DS, Jack CR, Dickson DW (2015) Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain 138, 1370-1381
2. Bradley KM, O'Sullivan VT, Soper NDW, Nagy Z, King E-F, Smith AD, Shepstone BJ (2002) Cerebral perfusion SPET correlated with Braak pathological stage in Alzheimer's disease. Brain 125, 1772-1781
3. Jobst KA, Smith AD, Barker CS,Wear A, King EM, Smith A, Anslow PA, Molyneux AJ, Shepstone BJ, Soper N, Holmes KA, Robinson JR, Hope RA, Oppenheimer C, Brockbank K, McDonald B (1992) Association of atrophy of the medial temporal lobe with reduced blood flow in the posterior parietotemporal cortex in patients with a clinical and pathological diagnosis of Alzheimer's disease. J Neurol Neurosurg Psychiatry 55, 190-194
4. Mosconi L, Mistur R, Switalski R, Tsui WH, Glodzik L, Li Y, Pirraglia E, De Santi S, Reisberg B, Wisniewski T, Leon MJ (2009) FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nuc Med Mol Imaging 36, 811-822
5. Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM (2010) The clinical use of structural MRI in Alzheimer disease. Nat Rev Neurol 6, 67-77
6. Gertz H-J, Xuereb J, Huppert F, Brayne C, McGee MA, Paykel E, Harrington C, Mukaetova-Ladinska E, Arendt T, Wischik CM (1998) Examination of the validity of the hierarchical model of neuropathological staging in normal aging and Alzheimer's disease. Acta Neuropathol 95, 154-158
7. Mukaetova-Ladinska EB, Garcia-Sierra F, Hurt J, Gertz HJ, Xuereb JH, Hills R, Brayne C, Huppert FA, Paykel ES, McGee M, Jakes R, Honer WG, Harrington CR, Wischik CM (2000) Staging of cytoskeletal and b-amyloid changes in human isocortex reveals biphasic synaptic protein response during progression of Alzheimer's disease. Am J Pathol 157, 623-636
8. Wischik CM, Schelter BO, Wischik DJ, Storey JMD, Harrington CR (2017) Modelling prion-like processing of tau protein in Alzheimer's disease for pharmaceutical development. J Alzheimers Dis, [In Press]
9. Braak H, Zetterberg H, Tredici K, Blennow K (2013) Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-beta changes occur before increases of tau in cerebrospinal fluid. Acta Neuropathol 126, 631-641
10. Wischik CM, Edwards PC, Lai RYK, Roth M, Harrington CR (1996) Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 93, 11213-11218
11. Holmes BB, Furman JL, Mahan TE, Yamasaki TR, Mirbaha H, Eades WC, Belaygorod L, Cairns NJ, Holtzman DM, Diamond MI (2014) Proteopathic tau seeding predicts tauopathy in vivo. Proc Natl Acad Sci U S A 111, E4376-E4385
12. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259
13. Wischik CM, Staff RT, Wischik DJ, Bentham P, Murray AD, Storey JMD, Kook KA, Harrington CR (2015) Tau aggregation inhibitor therapy: An exploratory phase 2 study in mild or moderate Alzheimer's disease. J Alzheimers Dis 44, 705-720
14. Murray AD, Staff RT, Ahearn TS, Bentham P, Seng KM, Wischik C (2008) P4-384: Tau Aggregation Inhibitor (TAI) therapy with remberTM changes glucose metabolism in the medial temporal lobes in mild and moderate Alzheimer's disease (AD). Alzheimers Dement 4, T786
15. Baddeley TC, McCaffrey J, Storey JMD, Cheung JKS, Melis V, Horsley D, Harrington CR, Wischik CM (2015) Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer's disease. J Pharmacol Exp Ther 352, 110-118
16. Gauthier S, Feldman HH, Schneider LS, Wilcock GK, Frisoni GB, Hardlund JH, Moebius HJ, Bentham P, Kook KA, Wischik DJ, Schelter BO, Davis CS, Staff RT, Bracoud L, Shamsi K, Storey JMD, Harrington CR, Wischik CM (2016) Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: A randomised, controlled, double-blind, parallel-arm, phase 3 trial. Lancet 388, 2873-2884
17. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ (2011) The Columbia-Suicide Severity Rating Scale: Initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168, 1266-1277
18. Alusik S, Kalatova D, Paluch Z (2014) Serotonin syndrome. Neuroendocrinol Lett 35, 265-273
19. Ramsay RR, Dunford C, GillmanPK(2007) Methylene blue and serotonin toxicity: Inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction. Br J Pharmacol 152, 946-951
20. Leung KK, Bartlett JW, Barnes J, Manning EN, Ourselin S, Fox NC, for the Alzheimer's Disease Neuroimaging Initiative (2013) Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration. Neurology 80, 648-654
21. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, Kieburtz K, Raman R, Sun X, Aisen PS, Siemers E, Liu-Seifert H, Mohs R (2014) Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. New Eng J Med 370, 311-321
22. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, Sabbagh M, Honig LS, Porsteinsson AP, Ferris S, Reichert M, Ketter N, Nejadnik B, Guenzler V, Miloslavsky M, Wang D, Lu Y, Lull J, Tudor IC, Liu E, Grundman M, Yuen E, Black R, Brashear HR (2014) Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease. New Eng J Med 370, 322-333
23. Murray AD, Staff RT, McNeil CJ, Salarirad S, Ahearn TS, Mustafa N, Whalley LJ (2011) The balance between cognitive reserve and brain imaging biomarkers of cerebrovascular and Alzheimer's diseases. Brain 134, 3687-3696
24. Landau SM, Harvey D, Madison CM, Koeppe RA, Reiman EM, Foster NL, Weiner MW, Jagust WJ (2011) Associations between cognitive, functional, and FDG-PET measures of decline in AD and MCI. Neurobiol Aging 32, 1207-1218
25. Kilimann I, Grothe M, Heinsen H, Alho EJL, Grinberg L, Amaro Jr E, Santos GAB, Silva RE, Mitchell AJ, Frisoni GB, Bokde ALW, Fellgiebel A, Filippi M, Hampel H, Kloppel S, Teipel SJ (2014) Subregional basal forebrain atrophy in Alzheimer's disease: A multicenter study. J Alzheimers Dis 40, 687-700
26. Whalley LJ, Murray AD, Staff RT, Starr JM, Deary IJ, Fox HC, Lemmon H, Duthie SJ, Collins AR, Crawford JR (2011) How the 1932 and 1947 mental surveys of Aberdeen schoolchildren provide a framework to explore the childhood origins of late onset disease and disability. Maturitas 69, 365-372
27. Schneider LS, Insel PS, Weiner MW, for the Alzheimer's Disease Neuroimaging Initiative (2011) Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer's Disease Neuroimaging Initiative. Arch Neurol 68, 58-66
28. Kawakami I, Hasegawa M, Arai T, Ikeda K, Oshima K, Niizato K, Aoki N, Omi K, Higashi S, Hosokawa M, Hirayasu Y, Akiyama H (2014) Tau accumulation in the nucleus accumbens in tangle-predominant dementia. Acta Neuropathol Commun 2, 40
29. Sassin I, Schultz C, Thal DR, Rub U, Arai K, Braak E, Braak H (2000) Evolution of Alzheimer's disease-related cytoskeletal changes in the basal nucleus of Meynert. Acta Neuropathol 100, 259-269
30. Schmitz TW, Spreng RN (2016) Basal forebrain degeneration precedes and predicts the cortical spread of Alzheimer's pathology. Nat Commun 7, 13249
31. Tanaka Y, Hanyu H, Sakurai H, Takasaki M, Abe K (2003) Atrophy of the substantia innominata on magnetic resonance imaging predicts response to donepezil treatment in Alzheimer's disease patients. Dementia Geriat Cognit Disord 16, 119-125
32. Cavedo E, Grothe MJ, Colliot O, Lista S, Chupin M, Dormont D, Houot M, Lehericy S, Teipel S, Dubois B, Hampel H (2017) Reduced basal forebrain atrophy progression in a randomized Donepezil trial in prodromal Alzheimer's disease. Sci Rep 7, 11706
33. Huang M, Felix AR, Flood DG, Bhuvaneswaran C, Hilt D, Koenig G, Meltzer HY (2014) The novel 7 nicotinic acetylcholine receptor agonist EVP-6124 enhances dopamine, acetylcholine, and glutamate efflux in rat cortex and nucleus accumbens. Psychopharmacology 231, 4541-4551
34. Picciotto MR, Higley MJ, Mineur YS (2012) Acetylcholine as a neuromodulator: Cholinergic signaling shapes nervous system function and behavior. Neuron 76, 116-129
35. Shearman E, Rossi S, Szasz B, Juranyi Z, Fallon S, Pomara N, Sershen H, Lajtha A (2006) Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study. Brain Res Bull 69, 204-213
36. Lewis DA, Campbell MJ, Terry RD, Morrison JH (1987) Laminar and regional distributions of neurofibrillary tangles and neuritic plaques in Alzheimer's disease: A quantitative study of visual and auditory cortices. J Neurosci 7, 1799-1808
37. Harrington CR, Storey JMD, Clunas S, Harrington KA, Horsley D, Ishaq A, Kemp SJ, Larch CP,Marshall C, Nicoll SL, Rickard JE, Simpson M, Sinclair JP, Storey LJ, Wischik CM (2015) Cellular models of aggregation-dependent template-directed proteolysis to characterize tau aggrega tion inhibitors for treatment of Alzheimer's disease. J Biol Chem 290, 10862-10875
38. Herrmann M, Golombowski S, Krauchi K, Frey P,Mourton-Gilles C, Hulette C, Rosenberg C, Muller-Spahn F, Hock C (1999) ELISA-quantitation of phosphorylated tau protein in the Alzheimer's disease brain. Eur Neurol 42, 205-210
39. Lai RYK, Gertz H-J, Wischik DJ, Xuereb JH, Mukaetova-Ladinska EB, Harrington CR, Edwards PC, Mena R, Paykel ES, Brayne C, Huppert FA, Roth M, Wischik CM (1995) Examination of phosphorylated tau protein as a PHFprecursor at early stage Alzheimer's disease. Neurobiol Aging 16, 433-445
40. Khatoon S, Grundke-Iqbal I, Iqbal K (1992) Brain levels of microtubule-associated protein t are elevated in Alzheimer's disease: A radioimmuno-slot-blot assay for nanograms of the protein. J Neurochem 59, 750-753
41. Congdon EE, Wu JW, Myeku N, Figueroa YH, Herman M, Marinec PS, Gestwicki JE, Dickey CA, Yu WH, Duff KE (2012) Methylthioninium chloride (methylene blue) induces autophagy and attenuates tauopathy in vitro and in vivo. Autophagy 8, 609-622
42. Atamna H, Atamna W, Al-Eyd G, Shanower G, Dhahbi JM (2015) Combined activation of the energy and cellulardefense pathways may explain the potent anti-senescence activity of methylene blue. Redox Biol 6, 426-435
43. Bruchey AK, Gonzalez-Lima F (2008) Behavioral, physiological and biochemical hormetic responses to the autoxidizable dye methylene blue. Am J Pharmacol Toxicol 3, 72-79
44. Gharid A, Atamna H (2011) Methylene blue induces mitochondrial complex IV and improves cognitive function and grip strength in old mice. In Neurodegeneration: Theory, Disorders and Treatments, McNeill AS, ed. AS Nova Science Publishers, Hauppauge, NY, pp. 63-85
45. Lee KK, Boelsterli UA (2014) Bypassing the compromised mitochondrial electron transport with methylene blue alleviates efavirenz/isoniazid-induced oxidant stress and mitochondria-mediated cell death in mouse hepatocytes. Redox Biol 2, 599-609
46. Rojas JC, Bruchey AK, Gonzalez-Lima F (2012) Neurometabolic mechanisms for memory enhancement and neuroprotection of methylene blue. Prog Neurobiol 96, 32-45
47. Xiong Z-M, Choi JY,Wang K, Zhang H, Tariq Z,Wu D, Ko E, LaDana C, Sesaki H, Cao K (2016) Methylene blue alleviates nuclear and mitochondrial abnormalities in progeria. Aging Cell 15, 279-290
48. Zakaria A, Hamdi N, Abdel-Kader RM (2016) Methylene blue improves brain mitochondrial ABAD functions and decreases A in a neuroinflammatory Alzheimer's disease mouse model. Mol Neurobiol 53, 1220-1228
49. Zhang X, Rojas JC, Gonzalez-Lima F (2006) Methylene blue prevents neurodegeneration caused by rotenone in the retina. Neurotox Res 9, 47-57
50. Melis V, Magbagbeolu M, Rickard JE, Horsley D, Davidson K, Harrington KA, Goatman K, Goatman EA, Deiana S, Close SP, Zabke C, Stamer K, Dietze S, Schwab K, Storey JMD, Harrington CR, Wischik CM, Theuring F, Riedel G (2015) Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models. Behav Pharmacol 26, 353-368
51. Stack C, Jainuddin S, Elipenahli C, Gerges M, Starkova N, Starkov AA, Jove M, Portero-Otin M, Launay N, Pujol A, Kaidery NA, Thomas B, Tampellini D, Beal MF, Dumont M (2014) Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity. Hum Mol Genet 23, 3716-3732
52. Rodriguez P, Zhou W, Barrett DW, Altmeyer W, Gutierrez JE, Li J, Lancaster JL, Gonzalez-Lima F, Duong TQ (2016) Multimodal randomized functional MR imaging of the effects of methylene blue in the human brain. Radiology 281, 516-526
53. Rodriguez P, Singh AP, Malloy KE, Zhou W, Barrett DW, Franklin CG, Altmeyer WB, Gutierrez JE, Li JQ, Heyl BL, Lancaster JL, Gonzalez-Lima F, Duong TQ (2017) Methylene blue modulates functional connectivity in the human brain. Brain Imaging Behav 11, 640-648
54. Larner AJ (1997) The cerebellum in Alzheimer's disease. Dement Geriat Cogn Disord 8, 203-209
55. Benson K, Hartz AJ (2000) A comparison of observational studies and randomized, controlled trials. New Engl J Med 342, 1878-1886
56. Winblad B, Amouyel P, Andrieu S, Ballard C, Brayne C, Brodaty H, Cedazo-Minguez A, Dubois B, Edvardsson D, Feldman H, Fratiglioni L, Frisoni GB, Gauthier S, Georges J, Graff C, Iqbal K, Jessen F, Johansson G, Jonsson L, Kivipelto M, Knapp M, Mangialasche F, Melis R, Nordberg A, Rikkert MO, Qiu C, Sakmar TP, Scheltens P, Schneider LS, Sperling R, Tjernberg LO, Waldemar G, Wimo A, Zetterberg H (2016) Defeating Alzheimer's disease and other dementias: A priority for European science and society. Lancet Neurol 15, 455-532